20 years of intensive experience in Global Oncology Clinical Development, Registration Submission and Product Launch;
Merck & Co., Inc. (Upper Gwynedd PA, USA) clinical research scientist in Oncology Clinical Department, major clinical contributor for MAA submission preparation of vorinostat in Merck Oncology;
Novartis Oncology Business Unit (Florham Park NJ, USA) Global Clinical Trial Head of burparlisib (BKM120), completed the first-in-man trial significantly ahead of timeline, winner of Novartis President Award, managing multiple global phase II PoC trials and Phase III pivotal trial of burparlisib (BKM120) in Breast Cancer, Glioblastoma, and NSCLC for consecutive 6 years;
Exelixis (South San Francisco CA, USA) Senior Director, Clinical Science Lead of Phase III pivotal trial METEOR, which was granted BTD, Priority Review and Rolling Submission by the US FDA, and the Accelerate Assessment by the EU EMA;
Pfizer Oncology Late Phase Clinical Development (La Jolla CA, USA) Senior Director, Hematology Asset Team Lead, “CEO” of inotuzumab ozogamicin Global Asset Team, timely delivered two top line reports for Phase III pivotal INO-VATE trial, which was granted BTD, Priority Review and Rolling Submission by the US FDA, and timely submitted inotozumab ozogamicin MAA to the EU EMA;
Sihuan Pharmaceutical Holding Group Ltd. (Beijing, China) Chief Scientific Officer, General Manager of Clinical Center;
Principle scientist and sub-investigator of Clinical Breast Care Project (CBCP), a breast cancer vaccination clinical development program sponsored by the US Department of Defense and cofounded by Walter Reed Army Medical Center (Washington DC) and Windber Medical Center (Windber PA), prior to joining in the global pharmaceutical industry;
Ph.D degree in Chemistry from Tsinghua University；Post-Doctoral training in the US Department of Defense sponsored Los Alamos National Laboratory Bioscience Division.